- Volume 17 Issue 4
Breast cancer is the most common cause of cancer-related death among women in the whole world. MiR- 34a and let-7a are well known tumor suppressors that participate in the regulation of apoptosis, invasion and other cellular functions. In this study, expression of miR-34a, let-7a and apoptosis pathway genes such as Bcl-2, Caspase-3 and P53 were evaluated using quantitative real-time PCR in 45 paired samples of normal margin and tumor tissue collected from breast cancer patient at advanced stage (3-4). MiR-34a, let-7a, caspase-3 and P53 expression are reduced and Bcl-2 expression is increased within tumoral tissues in comparison with normal margin tissues. P53 expression directly or indirectly was correlated with miR-34a, let-7a, Bcl-2 and caspase-3 expression. In This study we found that MiR-34a and let-7a expression are reduced in the tumoral tissues. Down-regulation of these two molecules correlated with expression of genes associated with apoptosis. These results suggest that due to the correlation of miR-34a and let-7a with apoptotic and anti-apoptotic pathways these molecules could participate as regulators in advanced clinical stages of breast cancer and should be considered as markers for diagnosis, prognostic assessment and targeted therapy.
- Bussing I, Slack FJ, Grosshans H (2008). let-7 microRNAs in development, stem cells and cancer. Trends Molecular Med, 14, 400-9. https://doi.org/10.1016/j.molmed.2008.07.001
- Chou J, Shahi P, Werb Z (2013). microRNA-mediated regulation of the tumor microenvironment. Cell Cycle, 12, 3262-71. https://doi.org/10.4161/cc.26087
- Costa PM, Pedroso de Lima MC (2013). MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression. Pharmaceuticals, 6, 1195-220. https://doi.org/10.3390/ph6101195
- Davis S, Lollo B, Freier S, et al (2006). Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res, 34, 2294-304. https://doi.org/10.1093/nar/gkl183
- Fang Y, Gao W (2014). Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene, 33, 135-47. https://doi.org/10.1038/onc.2013.54
- Fridman JS, Lowe SW (2003). Control of apoptosis by p53. Oncogene, 22, 9030-40. https://doi.org/10.1038/sj.onc.1207116
- Garzon R, Calin GA, Croce CM (2009). MicroRNAs in cancer. Annual Review Med, 60, 167-79. https://doi.org/10.1146/annurev.med.59.053006.104707
- Giono LE, Manfredi JJ (2006). The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cellular Physiol, 209, 13-20. https://doi.org/10.1002/jcp.20689
- Hannafon BN, Sebastiani P, de las Morenas A, et al (2011). Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res, 13, 24.
- Iorio MV, Casalini P, Tagliabue E, et al (2008). MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer, 44, 2753-9. https://doi.org/10.1016/j.ejca.2008.09.037
- Kumar MS, Erkeland SJ, Pester RE, et al (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA, 105, 3903-8. https://doi.org/10.1073/pnas.0712321105
- Mansoori B, Mohammadi A, Shirjang S, et al (2014). Micro- RNAs: The new potential biomarkers in cancer diagnosis, prognosis and cancer therapy. Cellular Molecular Biol, 61, 1-10.
- Ong CC, Gierke S, Pitt C, et al (2015). Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res, 17, 59. https://doi.org/10.1186/s13058-015-0564-5
- Peltier HJ, Latham GJ (2008). Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA, 14, 844-52. https://doi.org/10.1261/rna.939908
- Reis LO, Pereira TC, Lopes-Cendes I, et al (2010). MicroRNAs: a new paradigm on molecular urological oncology. Urol, 76, 521-7. https://doi.org/10.1016/j.urology.2010.03.012
- Shi X-B, Tepper CG, deVere White RW (2008). Cancerous miRNAs and their regulation. Cell Cycle, 7, 1529-38. https://doi.org/10.4161/cc.7.11.5977
- Thun MJ, DeLancey JO, Center MM, et al (2010). The global burden of cancer: priorities for prevention. Carcinogenesis, 31, 100-10. https://doi.org/10.1093/carcin/bgp263
- Yao Y, Hu J, Shen Z, et al (2015). MiR 200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. J Cellular Molecular Med, 19, 760-9. https://doi.org/10.1111/jcmm.12432
- Yu F, Yao H, Zhu P, et al (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-23. https://doi.org/10.1016/j.cell.2007.10.054
- Zenz T, Mohr J, Eldering E, et al (2009). miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 113, 3801-8. https://doi.org/10.1182/blood-2008-08-172254
- Zhang D-G, Zheng J-N, Pei D-S (2014). P53/microRNA- 34-induced metabolic regulation: new opportunities in anticancer therapy. Molecular Cancer, 13, 1-7. https://doi.org/10.1186/1476-4598-13-1
- Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells pp.1551-4005, 2017, https://doi.org/10.1080/15384101.2017.1387699